Tyra Biosciences reports Q3 net loss $21.2M; cash $215.7M; advances TYRA-300 and TYRA-200 trials

Tyra Biosciences, Inc.

2023-Q3 EPS reported -$1.09

Q3 2023 net loss $21.2M vs $12.5M YoY; R&D expenses $19.3M (prior $10.9M).
Cash and equivalents $215.7M as of Sept 30, 2023; funds operations for at least two years.
SURF301 Phase 1/2 for TYRA-300 (FGFR3 inhibitor) dose escalation ongoing; preclinical achondroplasia data positive.
TYRA-200 Phase 1 in FGFR2-altered cholangiocarcinoma on track to dose first patient by YE 2023.
FDA granted TYRA-300 Orphan Drug Designation for achondroplasia in July 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tyra Biosciences, Inc. reported the quarter ended September 30, 2023 results: net income Third quarter 2023 net loss was $21.2 million.

Period: the quarter ended September 30, 2023
Net income: Third quarter 2023 net loss was $21.2 million
Result: reported results

Exact text from the filing

Third quarter 2023 net loss was $21.2 million compared to $12.5 million for the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.